Bevacizumab
Treatment for Ovarian Cancer
Typical Dosage: 15 mg/kg IV q3w
Effectiveness
70%
Safety Score
45%
Clinical Trials
258
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
15 mg/kg IV q3w
Time to Effect
1-3 months
Treatment Duration
12-15 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$115,000
Monitoring:$8,000
Side Effect Mgmt:$4,000
Total Annual:$127,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
2.2
Outcome-Based Costs
Cost per Responder
$211,667
Cost per Remission
$635,000
Comparison vs Carboplatin + Paclitaxel
Cost Difference
+$107,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Bevacizumab Outcomes
for Ovarian Cancer
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+60%
Remission Rate
+20%
Common Side Effects
Hypertension
+30%
Proteinuria
+20%
Fatigue
+40%
Nausea/Vomiting
+15%
Gastrointestinal perforation
+3%
Bleeding
+15%
Sources:
Active Clinical Trials
7 active trials recruiting for Bevacizumab in Ovarian Cancer
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
NCT06121401ACTIVE NOT RECRUITINGPHASE4
190 participants
INTERVENTIONAL
San Fermo della Battaglia, Italy +1 more
Started: Sep 15, 2023
RC48 in Combination With AK104 and Bevacizumab in OCCC
NCT06540729RECRUITINGPHASE2
39 participants
INTERVENTIONAL
Guanzhou, China
Started: Sep 24, 2024
Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency
NCT06827353RECRUITING
300 participants
OBSERVATIONAL
Nîmes, France
Started: Oct 1, 2020
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
NCT04787289RECRUITINGPHASE2
244 participants
INTERVENTIONAL
Abbotsford, Canada +1 more
Started: Sep 10, 2021
A Clinical Trial of Sacituzumab Tirumotecan in People With Ovarian Cancer (MK-2870-021)
NCT07318558NOT YET RECRUITINGPHASE3
900 participants
INTERVENTIONAL
Started: Feb 25, 2026
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
NCT07278336RECRUITINGPHASE1
207 participants
INTERVENTIONAL
San Antonio, United States +6 more
Started: Nov 27, 2025
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
NCT02734004ACTIVE NOT RECRUITINGPHASE1, PHASE2
264 participants
INTERVENTIONAL
Newnan, United States +46 more
Started: Mar 17, 2016
Completed Clinical Trials
9 completed trials for Bevacizumab in Ovarian Cancer
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
NCT05751629COMPLETEDPHASE2
41 participants
INTERVENTIONAL
Birmingham, United States +9 more
Started: Nov 15, 2018
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT03326193COMPLETEDPHASE2
105 participants
INTERVENTIONAL
Mobile, United States +28 more
Started: Dec 12, 2017
First Line Ovarian Cancer Treatment - Cohort Study
NCT01832415COMPLETED
500 participants
OBSERVATIONAL
Angers, France +13 more
Started: Apr 1, 2013
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
NCT02022917COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Chiayi City, Taiwan +4 more
Started: Mar 1, 2014
A Phase I Clinical Trial of Bevacizumab Injection
NCT05476341COMPLETEDPHASE1
98 participants
INTERVENTIONAL
Changchun, China
Started: Apr 6, 2017
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
NCT01735071COMPLETEDPHASE2
71 participants
INTERVENTIONAL
Brescia, Italy +6 more
Started: Jul 1, 2013
Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients
NCT00127920COMPLETEDPHASE2
20 participants
INTERVENTIONAL
Newport Beach, United States +1 more
Started: Aug 1, 2004
Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
NCT00130520COMPLETEDPHASE2
40 participants
INTERVENTIONAL
Tucson, United States
Started: Jun 1, 2005
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
NCT02659384COMPLETEDPHASE2
122 participants
INTERVENTIONAL
Paris, France +11 more
Started: Dec 23, 2016
Showing 20 of 263 total trials